Index

A
Accepting behaviors, 65, 66
Affective gender confusion, 24
Amsterdam clinic, 34
Anabolic steroid, 182
Anxiety, 63, 140
  clinical care, 130
  diagnosis and assessment, 78–81
  DSM diagnosis, 136
  endocrinologist, 139
  gender development history, 132–134
  hormonal intervention, 140
  hormone treatment, 130, 137
  irreversible medical interventions, 141
  management, 81
  medication, 139
  mental status examination, 135
  parent’s role, 141, 142
  parents support, 138, 139
  patient history, 129, 131, 132
  preliminary biopsychosocial formulation, 136, 137
  psychiatric history, 132
  psychosocial factors, 134, 135
  puberty-blocking medication, 130
  school’s role, 139
  social anxiety, 138
  social transition, 138, 140
  symptoms, 131
  transgender support group, 139
Assessment sorting tool, 69
Assigned sex at birth, 4, 16, 34, 39, 76, 110, 122, 126, 204
Attention deficit hyperactivity disorder (ADHD), 191, 192, 194, 195, 198, 200–205
Child Behavior Checklist, 106
  child’s social development, 117
  cisgender children with, 107
  diagnosis and assessment, 108, 109
  formulation, 112, 113
  gender development history, 110, 111
  gender identity, 107
  management, 114, 115
  mental status exam, 112
  and oppositional defiant disorder, 115
  oppositionality, 115–117
  psychiatric history, 109, 110
  psychoeducation, 117
  psychosocial factors, 111, 112
  social gender transition, 107
  symptoms of, 107
Autism spectrum disorders (ASDs), 19, 109, 126, 127
  diagnosis and assessment, 124
  domains, 122
  evidence-based support, 122 (see also  Gender dysphoria)
  individuals with, 123
  intellectual disability, 123
  intense restricted interests, 125
  management, 125
  prevalence rates for, 122

B
Beck Depression Inventory (BDI-II) scores, 159
Bipolar disorder, 78, 80–82, 88, 121, 124, 137, 157, 191, 192, 194, 195, 197, 204, 206
Breast augmentation, 60
C
Child and adolescent psychiatrist (CAP), 1, 2, 31, 37, 41, 45, 203
Child Behavior Checklist (CBCL), 106, 158, 159, 161
Child-centered approach, 114
Childhood sexual abuse, 145–147, 152, 153
Cisgender, 4, 18, 32, 33, 53, 80, 84, 107, 130, 131, 140, 145, 147, 157, 158, 160, 166, 169, 172, 173, 202, 206
Cognitive gender confusion, 24
Cognitive processing therapy, 150, 151
Collaborative empiricism, 153
Complete androgen insensitivity syndrome (CAIS), 32
Congenital adrenal hyperplasia (CAH), 32
Cosmetic surgery, 60
Cross-gender hormone therapy, 4, 41, 55
Cross-sex hormone, 4, 56, 77, 82, 159, 176
Culture, 35, 64, 69, 72, 154, 167, 172, 174
Cycle of violence, 151

D
Depression, 63, 67
assessment, 78–81, 162–164, 167
characteristics, 172
coccurring disorders, 158, 159
diagnosis, 78–81, 162, 164, 167–171
gender-affirming interventions, 159
gender-nonconforming children, 172
management, 81
patient history, 161
prevalence, 158
self-directed violence, 160, 161
suicide, 158, 160–161, 167, 170, 172, 174, 176
treatment, 163–167, 171
Disorders of sex development (DSD), 32, 91–93, 99, 101, 102
Disruptive behavior disorder(s), 8, 106, 107, 115
Draw-a-Person test, 24
Down-Turner mosaicism, 101
diagnosis and assessment, 94–97
management, 97–99

E
Endocrine Society Guidelines, 5, 6, 12, 25, 54, 59
Endocrine Society state, 58
External genitalia, 96, 5, 32, 51, 99, 100

F
Family dynamics
advantages and dis advantages, 71–73
clinical relevance, 64
diagnosis and assessment
DSM 5 diagnosis, 68
gender development history, 67
history, 66
mental status, 68
preliminary biopsychosocial formulation, 68
psychiatric history, 66, 67
psychosocial factors, 67
external factors, 72
literature review, 64–66
transgender adolescent, 64
treatment course, 69–71
Family therapy approach, 65
Feminizing hormone therapy, 57, 100, 148, 150, 183
Fluorescence in situ hybridization (FISH) studies, 95
Follicle-stimulating hormone (FSH), 50, 97

G
Gastroenterology evaluation, 97
Gay, Lesbian, or Whatever! (GLOW) group, 162
Gender-affirmative therapy, 147, 154
Gender-affirming sex hormone therapy, 53, 57, 59
Gender and Sex Development Program (GSDP), 92, 94, 95, 98, 102
Gender binary, 35, 45, 75, 77, 85
Gender discordance, see Gender incongruence
Gender-diverse, 92, 94
Gender diversity, 3, 11, 16, 20, 35, 40, 73, 88, 93, 98, 107, 189, 204
Gender dysphoria (GD), 2, 3, 6, 8, 10–13, 16–24, 53, 69, 106, 107, 115, 127, 129, 157, 181, 189
anxiety (see Anxiety)
CAP, 2
coccurring disease (see Multiple psychiatric co-occurring conditions)
Criterion A1, 33
definition, 4, 122 (see also Down-Turner mosaicism)
depression (see Depression)
diagnosis and assessment, 124 (see also Family dynamics)
DSM, 92, 93
DSM-5 criteria, 33
in adolescents and adults, 6–8
in children, 6–8
gender identity interview, 13–15
gender-informed assessment
  affirmative gender-informed assessment, 3
  age-appropriate assessment, 12
binary gender roles, 18
children and adolescents,
  biopsychosocial assessment of, 11
collateral information, 12, 13
co-occurring psychological/psychiatric issue, 2
coping strategies, 20, 22
documentation, 13
Endocrine Society Guidelines, 6
family dynamics, 20, 21
gender-affirming medical intervention, 2
gender assessment, 3
gender identity, 19
length, 10, 11
pronouns and name use, 16, 17
psychopharmacological assessment, 3
psychopharmacological intervention, 2, 3
psychosocial and community factors, 22, 23
pubertal suppression, 12
readiness assessment, 3
sexual orientation, 18, 19
timing, 12
youth, biopsychosocial assessment of, 6
gender nonbinary adolescent, identities and, 76, 77
hormonal and surgical interventions, 24–27
individuals with, 122, 123, 126
management, 69, 124, 125
MHP, 2, 5, 6
prepubertal children, 106
ADHD (see Attention deficit hyperactivity disorder (ADHD))
disruptive behavior disorder, 106, 107, 115
prepubertal gender dysphoria, 33
PSD (see Psychotic spectrum disorder)
psychometric instruments
  for adolescents, 24
  for children, 24
psychopathology, 8, 9
puberty suppression (see Puberty suppression)
restricted interests, 126
treatment, 127
surgical gender transition, 33
youth, 158–161, 176
Gender fluid, 4, 82, 84, 132, 135, 161–163, 165, 167, 168, 170
Gender identity interview
  for adolescent, 14, 15
  for children, 24
  for prepubertal child, 14
Gender incongruence, 4, 6, 32, 54, 76, 173, 204
Gender-informed biopsychosocial assessment, 39, 43
Gender Minority Stress and Resilience Scale (GMSR), 24
Gender nonbinary adolescent, 78–81
  anxiety and depression
diagnosis and assessment, 78–81
  management, 81
assessment, 83, 84
coccurring psychiatric conditions, 88
diagnosis, 82, 87
gender development history, 83–85
hormone treatment, 75
identities and gender dysphoria, 76, 77
management, 87–88
mental status exam, 85
psychiatric history, 83–84
psychosocial history, 86–87
unknown future effects, 88
Gender nonbinary, definition, 4
Gender-nonconforming behavior, 94, 97, 101, 102
Gender-nonconforming children, 150–154
  assessment, 148, 149
  childhood sexual abuse, 145–147, 152, 153
depression, 172
diagnosis, 147–149
minority stress, 145
patient history, 147
posttraumatic growth, 146
treatment
  CBT, 150, 153
gender-affirmative therapy, 154
  mid-treatment sessions, 150–152
termination/closure, 152–153
victimization and prejudice, 173
Gender nonconformity, 5, 92–95, 97, 101, 102
Gender reassignment, 5, 10, 12, 61, 166, 185, 186
Gender role, 5, 11, 14, 15, 18, 23, 37, 39, 41, 42, 61, 76, 77, 98, 107, 115, 127, 145, 162, 164, 172, 173
Genital surgery, 55, 60
GLSEN National School Climate Survey, 161
Gonadectomy, 96, 101, 102
Gonadotropin-releasing hormone analogues (GNRHa), 52
Gonadotropin-releasing hormone (GnRH), 50
GSDP, see Gender and Sex Development Program (GSDP)

H
Herman’s developmental stage model, 150, 154
Homosexuality, 19
Hormone-suppressing therapy, 54
Hormone therapy, 6, 27, 33, 41, 54–57, 59, 71, 147, 148, 150, 154, 190, 196, 197, 204
Hyperkalemia, 56

I
Impression management skills, 174, 175
Informed consent process, 60, 140, 190
Internal reproductive organs surgery, 60
Internal stressors, 65, 68, 71, 72
Internalized transphobia, 9, 44, 68, 152, 174, 175
Irreversible interventions, 52, 53, 88, 89, 127, 201
Irreversible medical interventions, 42, 42, 130, 131, 138, 141

L
Lesbian, gay, bisexual, and transgender (LGBT) community, 168, 186
LGBTQ youth, 184
Luteinizing hormone (LH), 50, 53, 97

M
Medical interventions
- estrogen effects and time course, 57
- gender-affirming sex hormone therapy, 57
- irreversible interventions, 52
- menstrual suppression, 57
- partially reversible interventions, 52
- puberty suppression
  - Amsterdam protocol, 53, 55
  - behavioral and emotional health, 54
  - clinical follow-up, 54
  - clinical manifestation, 55
  - co-occurring condition, 55
  - cross-gender hormone therapy, 55
  - fertility implications, 56
  - fMRI study, 55
  - gender-affirming sex hormones, 53
  - gender development, 54
  - hormone therapy, 54
  - hormone-suppressing therapy, 54
  - hypothetical risks, 54
  - hypothetical unknown effects, 56
  - metabolic and endocrine tests, 54
  - psychodiagnostic assessment, 54
  - psychological adjustment vs. cisgender adolescent controls, 53
  - sex hormone treatment, 53
  - surgical implications, 56
  - reversible androgen blocking, 56
  - reversible interventions, 52
  - reversible medications, 52
  - testosterone effects and time course, 58
  - top and bottom surgeries, 59, 60
Menstrual suppression, 26, 52, 56, 57
Mental health provider (MHP), 2, 5, 6, 10, 58, 61
Microaggressions, 65, 70
Minority stress, 8, 145, 147, 151, 182, 186, 190
Mixed gonadal dysgenesis (MGD), 96, 100
Müllerian structures, 96
Multiple psychiatric co-occurring conditions
  - biopsychosocial formulation, 195, 201, 202
  - challenges, 204
  - clinical criteria, 189
  - diagnosis, 191
  - DSM diagnosis, 194, 201
  - gender development history, 192, 193, 198, 199
  - legal factors, 199, 200
  - mental status examination, 194, 200, 201
  - minority stress, 190
  - patient history, 191, 198
  - psychiatric history, 192, 198
  - psychiatric interventions, 205
  - psychosocial factors, 193, 194, 199, 200
  - substance use, 190, 192, 193, 195, 196, 198, 203–205
  - treatment, 204
  - course, 196, 197, 202–204
  - plan, 206
  - response, 204

N
Non-suicidal self-injurious behavior (NSSI), 132, 160, 161, 170

O
Obsessive-compulsive disorder (OCD), 198, 203–205
Oppositional defiant disorder, 106, 115, 116, 191
Oral contraceptive pills, 52, 56
Index

P
Pansexual, 79, 84, 162, 163
Parents, Family, and Friends of Lesbians and Gays (PFLAG), 95
Partially reversible interventions, 52
Physical changes, 45, 50–51, 87, 176, 199
Posttraumatic growth, 146, 147, 153
Posttraumatic stress disorder (PTSD), 145, 146, 148, 150
Pre-exposure prophylaxis (PrEP), 152
Prepubertal gender dysphoria, 33
Psychoeducation, 94, 95, 113, 114, 117
Psychological outcomes, 55, 59
Psychosis, 181–183, 187
Psychotic spectrum disorder
assessment, 184
diagnosis, 183
diagnostic criteria, 187
gender affirmative care, 181
hormone treatment, 184
minority stress, 186
patient history, 183
psychiatric evaluation, 184
psychiatric symptoms, 181–183, 185
psychotic symptoms, 187
symptoms, 184
testosterone, 182
treatment, 185, 186
treatment challenges, 187
Pubertal stages, 50–51
Puberty suppression
advantages, 53
Amsterdam protocol, 53, 55
behavioral and emotional health, 54
clinical follow-up, 54
clinical manifestation, 55
co-occurring condition, 55
cross-gender hormone therapy, 55
fertility implications, 56
fMRI study, 55
gender-affirming sex hormones, 53
gender development, 54
GnRHa, 53, 55
hormone-suppressing therapy, 54
hormone therapy, 54
hypothetical risks, 54
hypothetical unknown effects, 56
metabolic and endocrine tests, 54
psychodiagnostic assessment, 54
psychological adjustment vs. cisgender adolescent controls, 53
sex hormone treatment, 53
surgical implications, 56

R
Reconstructive chest surgery, 60
Rejecting behaviors, 64, 65, 68–70
Reversible androgen blocking, 56–57
Reversible interventions, 26, 52, 53, 81, 88, 89, 126, 127, 201
Reversible medications, 52

S
Schizoaffective disorder, 181, 185, 186
Schizophrenia, 123, 157, 183, 186
Secretary’s Task Force on Youth Suicide, 160
Self-directed violence, 158–161, 172–177
Sex, definition of, 5
Sex-diverse, 92
Sex reassignment surgery, 5, 54
Sexual orientation, 5, 13, 18–19, 26, 44, 135, 165, 183
Sexual satisfaction, 59
Social gender transition, 32, 36–41, 44, 45
in adolescents, 41–44
definition, 31, 34
gender identity development
biological contributions, 32
hormonal influences, 32
neuroimaging studies, 32
uterine androgen exposure, 32
in prepubertal children
anxiety and depression, 38
gender-informed biopsychosocial assessment, 39
historical approaches, 36–38
hypothetical benefits and limitations, 39, 40
mental health provider, 40
openness and universal support, 41
private vs. secret, 40
psychoeducation, 39
psychopathology, 38
puberty suppression, 41
treatment management principles, 39
nonphysiological interventions, 46
psychological interventions
psychopharmacology, 45
supportive psychotherapy, 44, 45
sociocultural shifts, 34
Spironolactone, 26, 52, 56
SSRI trial, 163
Suicidal ideation, 190, 192, 194, 196, 198–201, 204
Suicide, depression, 158, 160, 161, 167, 170, 172, 174, 176
T
Tanner stages, 24, 51, 53
Transgender, 76
  definition, 5
  girl, 108
  male, 5
  woman, 5
Transgender adolescents
  medical interventions
    estrogen effects and time course, 57
    gender-affirming sex hormone therapy, 57–59
    irreversible interventions, 52
    menstrual suppression, 56, 57
    partially reversible interventions, 52
    puberty suppression, 53–56
    reversible androgen blocking, 56
    reversible interventions, 52
    reversible medications, 52
    testosterone effects and time course, 58
    top and bottom surgeries, 59–61
  natal female tanner stages, 51
  natal male tanner stages, 51
  physical changes, 50
  puberty changes, 50
Transition, definition of, 5
Transphobia, 9, 44, 68, 152, 173–175

Transsexual, 5, 76
Trauma recovery, 150, 151, 154
Trisomy 21, 95–97, 100

U
Utrecht Gender Dysphoria Scale
  (UGDS), 24

W
Walker’s three-stage model, 151
World Professional Association for
  Transgender Health Standards of Care, 24, 25, 58, 59, 190
World Professional Association of
  Transgender Health, Standards of Care 7th edition (WPATH SOC7), 46, 182

X
X-chromosome monosomy, 99

Y
Y chromosome mosaicism, 96, 100, 101